DBV Technologies SA DBV
EURONEXT · France · Health Technology
€2.01-0.07 (-3.18%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
European equities traded in the US as American depositary receipts were trending lower late Wednesda
Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population. DBV has requested Priority Review of the BLA. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, tod
European equities traded in the US as American depositary receipts were tracking slightly lower Thur
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.